QPPV.COM KNOWLEDGE ASSESSMENT

Professional Knowledge Assessment: Donanemab Classification, Mechanism, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Donanemab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best reflects the regulatory role of regional product information in donanemab pharmacovigilance?
Question 2 of 10 A report labels an event as 'immune-mediated' but provides no supporting clinical or laboratory evidence. What is the most appropriate professional response?
Question 3 of 10 A case report describes a neurological event occurring after donanemab, but gives no indication, treatment intent or disease-status information. What is the main pharmacovigilance concern?
Question 4 of 10 Which stratification would be most appropriate when reviewing whether an adverse-event pattern differs across patient groups?
Question 5 of 10 Why should an interruption of donanemab not automatically be treated as a complete dechallenge?
Question 6 of 10 Which statement best captures the role of temporal association in causality assessment?
Question 7 of 10 A periodic review pools cases from different indications and treatment combinations. What is the principal interpretive risk?
Question 8 of 10 Why is the distinction between deposited amyloid beta and a nonspecific immune stimulus important when assessing a suspected adverse reaction?
Question 9 of 10 A patient receiving donanemab also takes an antithrombotic medicine and has cerebral microhaemorrhages. How should this information be used?
Question 10 of 10 A cluster of cerebral imaging findings is observed in a specialised treatment population. What is the most appropriate next step?

Select an answer to continue.

QPPV.com